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A b s t r a c t
Antimicrobial peptides (AMPs) are cationic small peptide chains that have good antimicrobial activity against a variety of bacteria, fungi, 
and viruses. AMP-17 is a recombinant insect AMP obtained by a prokaryotic expression system. However, the full antifungal activity, 
physicochemical characteristics, and cytotoxicity of AMP-17 were previously unknown. AMP-17 was shown to have good antifungal 
activity against five pathogenic fungi, with minimum inhibitory concentrations (MIC) of 9.375–18.75 µg/ml, and minimum fungicidal 
concentrations (MFC) of 18.75–37.5 µg/ml. Notably, the antifungal activity of AMP-17 against Cryptococcus neoformans was superior to 
that of other Candida spp. In addition, the hemolytic rate of AMP-17 was only 1.47%, even at the high concentration of 16 × MIC. AMP-17 
was insensitive to temperature and high salt ion concentration, with temperatures of 98°C and –80°C, and NaCl and MgCl2 concentrations 
of 50–200 mmol/l, having no significant effect on antifungal activity. However, AMP-17 was sensitive to proteases, trypsin, pepsin, and 
proteinase K. The elucidation of antifungal activity, physicochemical properties and cytotoxicity of AMP-17 provided an experimental basis 
for its safety evaluation and application, as well as indicated that AMP-17 might be a promising drug.
K e y  w o r d s: antimicrobial peptides, AMP-17, antifungal activity, stability, hemolytic activity
Introduction
In recent years, the number of patients presenting 
with fungal infections has increased, and the emer-
gence of pathogenic fungi has seriously affected human 
health and safety. Of the several common pathogenic 
fungi that occur clinically, Candida spp., dominated by 
Candida albicans, and non-Candida spp., dominated 
by Cryptococcus neoformans, are the most common 
(Wang et al. 2012; Jensen 2016; Lovero et al. 2016). Can-
didiasis is mainly an acute, subacute or chronic infec-
tion caused by C. albicans. It is the most common fungal 
disease, often invading the skin and mucous mem-
branes, and can also cause visceral or systemic infec-
tions. The clinical symptoms are intricate and inconsist-
ent. However, cryptococcal infections are usually seen 
in patients with low immune function, especially in the 
case of acquired immunodeficiency syndrome (AIDS) 
and pulmonary tuberculosis (PTB) (Chopra et al. 2015). 
Non-candida disease is mainly caused by the invasion 
of C. neoformans spores into the respiratory tract, which 
subsequently causes hematogenous dissemination, 
leading to central nervous system infection (Lortholary 
et al. 2004; Burnik et al. 2007). Patients with cryptococ-
cal lung infection often develop non-specific symptoms 
such as weight loss, fever, cough, and general weakness. 
Moreover, clinical manifestations vary from asymp- 
tomatic infection to severe pneumonia and respira-
tory failure (Brizendine et al. 2011; Debenedectis et al. 
2013). At present, azoles, polyenes, echinocyclines, and 
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fluorocytosines are the most commonly used drugs for 
the treatment of fungal infections; however, all have cer-
tain toxicity and side effects, and drug-resistant strains 
are constantly emerging. (Bellmann and Smuszkiewicz 
2017; Spitzer et al. 2017). Therefore, the development 
of new antifungal drugs is urgently needed for clinical 
anti-infection treatment.
Antimicrobial peptides (AMPs), also known as 
host defense peptides, are biologically active mole-
cules produced by various organisms as important 
components of their innate immune response (Yan 
et al. 2018). AMPs not only have strong antimicrobial 
efficacy but also have activity against viruses, parasites 
and tumor cells (Ren et al. 2012; Patnaik et al. 2013; 
Tindwa et al. 2013). In addition to strong antimicro-
bial efficacy, AMPs have low hemolytic and cytotoxic 
activities (Edwards et al. 2016). For example, Quin-
tana et al. (2014) found that the AMP subtilosin has 
antiviral and viricidal effects against herpes simplex 
virus type 2 (HSV-2). Kovalchuk et al. (2007) showed 
that a complex of natural cytokines and AMPs (CCAP 
or Superlymph) inhibits virus proliferation in vitro. 
Therefore, due to their small molecular weight, good 
thermal stability and broad antimicrobial spectrum, 
AMPs are expected to replace antibiotics as new and 
highly effective antibacterial drugs (Presicce et al. 2009; 
Seydlová et al. 2017).
AMP-17 is encoded by a specific highly expressed 
gene extracted from the Musca domestica transcriptome 
database constructed after 12 h of microbial infection. 
The AMP-17 gene has no functional annotation in 
GeneBank and is of unknown function. To further 
assess the antimicrobial activity of the protein encoded 
by this gene, the prediction tools of the Antimicrobial 
Peptide (APD) and Collection of Anti-Microbial Pep-
tides (CAMP) databases were used (Wang et al. 2004; 
Thomas et al. 2010; Wang et al. 2016). The two databases 
used four different algorithms, support vector machines 
(SVM), random forest (RF), artificial neural networks 
(ANN), and discriminant analysis (DA) to predict the 
protein structure, and the scores obtained were 1, 0.944, 
1 and 1, respectively. All the results determined that the 
protein was an AMP. The antifungal function of recom-
binant AMP-17 protein has been reported by Guo et al. 
(2017) who showed its strong activity against C. albi-
cans, indicating it had good development potential.
In this study, the in vitro antifungal activity of 
AMP-17 protein was assessed against C. albicans, Can-
dida krusei, Candida tropicalis, Candida parapsilosis, 
and C. neoformans. To further understand the physical 
and chemical properties of AMP-17 protein, the salt, 
acid-base, and thermal stabilities were also assayed. In 
addition, cytotoxicity and hemolytic activity of AMP-17 
protein were determined, as a prelude to more extensive 
safety evaluation.
Experimental
Materials and Methods
Materials. AMP-17 protein was obtained from the 
Guoguo research team. It was produced in a prokaryotic 
expression system and purified by a nickel ion metal 
chelator affinity chromatography (Guo et al. 2017). Flu-
co nazole (FLC), Sabouraud dextrose agar (SDA) and 
Sabouraud dextrose broth (SDB) were purchased from 
Solarbio (Beijing, China). Human red blood cells were 
donated by the Affiliated Hospital of Guizhou Medical 
University, Guiyang, China.
Microbial strains. C. albicans ATCC 10231 was 
routinely preserved by the Key Laboratory of Mod-
ern Pathogenic Biology, Guizhou Medical University, 
Guiyang, China). C. krusei IFM56881, C. tropicalis 
IFM57016, C. parapsilosis ATCC 22019, and C. neofor-
mans IFM51426 were obtained from the Department 
of Microbiology, Guizhou Medical University, Guiyang, 
China. They were stored in 30% glycerol at –80°C.
MIC determination. A single actively growing 
microbial colony was inoculated into 5 ml sterile SDB 
medium and incubated overnight at 37°C. The turbidity 
of the fungal solution was adjusted to 1–5 × 106 colony-
forming units (CFU)/ml using a blood cell counting 
plate. The fungal suspension was then diluted with SDB 
to 0.5–2.5 × 103 CFU/ml. An aliquot of 100 μl of the 
final suspension was added into each well of a sterile 
96-well plate containing 100 μl of medium containing 
antimicrobial agents at double-diluted concentrations. 
Phosphate-buffered saline (PBS) was used as a nega-
tive control and fluconazole as a positive control. The 
plate was assessed for MIC values of AMP-17 after 
24 h or 48 h of incubation at 37°C. The MIC value was 
determined to be the minimum concentration at which 
microscopic growth could not be observed by the naked 
eye, as recommended by the Clinical Laboratory and 
Standards Institute CLSI (2008) methods (Cantón et al. 
2008; Fothergill 2012). The experiment was repeated 
three times, three biological replicates at a time.
MFC determination. Based on the MIC value, the 
criteria for fungal MFC values were slightly adjusted. 
Briefly, samples from each well of a 96-well plate, pre-
pared as described above, were used to determine MFC. 
Ten μl samples were plated on SDA, with CFUs being 
counted after incubation at 37°C for 24 h (C. albicans, 
C. krusei, C. tropicalis, C. parapsilosis) or 48 h (C. neofor-
mans). The experiment was repeated three times, three 
biological replicates at a time.
Time-kill curves. Overnight cultures of fungi 
were diluted in sterile SDB medium and adjusted to 
1–5 × 106 CFU/ml. An aliquot of 100 μl of this fungal 
suspension was added to a 96-well plate containing 
900 μl of a specific concentration of AMP-17 and then 
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incubated at 37°C. The optical density of the culture was 
recorded every two hours at a wavelength of 562 nm. 
With different sampling time (h) as the abscissa, the 
A562 value of each plate well was plotted on the ordi-
nate, generating a time-kill curve. PBS and fluconazole 
were used as negative and positive controls, respec-
tively. The experiment was repeated three times, three 
biological replicates at a time.
Determination of salt ion strength stability. An 
overnight culture of C. albicans was diluted in sterile 
SDB medium and adjusted to 1.0 – 2.5 × 103 CFU/ml. 
One hundred μl of this fungal suspension was added 
to a  96-well plate, where each well contained 100 μl 
of AMP-17, at 1–6 × MIC, and NaCl or MgCl2 at final 
concentrations of 0, 50, 100, and 200 mmol/l. The MIC 
value of AMP-17 against C. albicans, under the influ-
ence of different concentrations of NaCl or MgCl2, was 
determined as recommended by the CLSI (2008) meth-
ods. The experiment was repeated three times, three 
biological replicates at a time.
Determination of heat stability and freeze-thaw 
resistance. An overnight culture of C. albicans was dilu- 
ted in sterile SDB and adjusted to 1.0 – 2.5 × 103 FU/ml. 
One hundred μl AMP-17, at 1 × MIC, was maintained at 
98°C in a water bath for 5, 20, 30, 60, 90, and 120 min-
utes (heat-resistant group). One hundred μl AMP-17, at 
1 × MIC was also repeatedly frozen at –80°C, 1, 2, 4, 6, 8, 
and 10 times (freeze-thawed group). One hundred μl ali-
quots of the fungal suspension were added to a 96-well 
plate containing the heat-resistant group, the freeze-
thawed group, and a negative control group, and incu-
bated at 37°C for 24 hours. Ten μl samples from the heat-
resistant group plate were then directly inoculated onto 
SDA, and CFU counts were taken after incubation at 
37°C for 24 h. Samples taken from the freeze-thaw group 
and the negative control group were diluted 1:10 000, 
and then 100 μl was plated on SDA. CFU counts were 
taken after incubation at 37°C for 24 h. ddH20 was used 
as a negative control. The experiment was repeated three 
times, three biological replicates at a time.
Stability to treatment with trypsin, pepsin and pro-
teinase K. An overnight culture of C. albicans was dilu- 
ted in sterile SDB and adjusted to 1.0 – 2.5 × 103 CFU/ml 
Fifty μl 0.1 mg/ml proteases (the pH values of trypsin, 
pepsin, and protease K solutions were: 7, 5, and 7, 
respectively) and 50 μl 37.5 μg/ml AMP-17 (2 × MIC) 
were mixed in a 96-well plate and placed in a 37°C 
water bath for 2 min, 20 min, 40 min, 60 min, 80 min, 
100 min, and 120 min. One hundred μl of the fungal 
suspension was then added to the 96-well plate, fol-
lowed by incubation at 37°C for 18 h. Subsequently, 
10 μl of the fungal suspension was diluted 1:10 000, 
and 50 μl of this was incubated on SDA for 24 hours, 
followed by CFU counting. PBS was used as a negative 
control. The experiment was repeated three times, three 
biological replicates at a time.
Determination of hemolytic activity. Hemolytic 
activity of AMP-17 was evaluated using the method of 
Souza et al. (2013). Briefly, freshly isolated and washed 
human erythrocyte suspensions were diluted with 
0.01 M PBS, pH 7.4, and then centrifuged at 125 × g and 
4°C for 10 min. This process was repeated three times. 
The final pellets were resuspended in PBS at a concen-
tration of 4% (v/v). One hundred μl of different con-
centrations of AMP-17 (2.344–300 μg/ml) was added 
to a  96-well plate containing 100 μl 4% human red 
blood cell suspension, and this was incubated at 37°C 
for 1 h and then centrifuged (225 × g, 4°C, 10 min). The 
absorbance of the supernatants at 450 nm was then 
measured using an ultra-microplate spectrophotometer 
(Model: US Biotekepoch 2). PBS (0.01 M) was used as 
a negative control and 0.1% Triton X-100 was a positive 
control. The experiment was repeated three times, three 
biological replicates at a time. Percentage hemolysis was 
determined by the formula:
Hemolysis (%) = [(Abs450 in the peptide solution
 – Abs450 in PBS) / (Abs450 in 0.1%
 Triton X-100 – Abs450 in PBS)] × 100
Statistical analysis. Statistical differences were 
analyzed using the GraphPad Prism 6 software. The 
comparison between groups was carried out by using 
a  Student’s t-test. The p-value < 0.05 was statistically 
significant. All data for the experiment were expressed 
as mean ± SD.
Results
Antifungal activity of AMP-17. In a previous study, 
AMP-17 was shown to have strong antifungal activity 
against C. albicans ATCC76615, with a MIC of 2 μg/ml 
(Guo et al. 2017). To further validate its antifungal 
effect against several common clinical pathogens, 
actively growing fungal cells of C. albicans, C. tropi- 
calis, C. krusei, C. parapsilosis, and C. neoformans) 
were treated with purified AMP-17 protein. Notably, 
100 μg/ml AMP-17 could inhibit or kill C. albicans, 
C. tropicalis, C. krusei, C. parapsilosis, and C. neoformans 
in SDB medium. Compared to the PBS negative control, 
AMP-17 showed antifungal activity against each fungus 
from 2 to 24 h of culture. When fungi were cultured 
for 24 h, the fungicidal effect of AMP-17 was slightly 
different between species. The fungicidal curves of 
C. albicans and C. tropicalis increased slightly, but were 
lower than the PBS control group, while the fungicidal 
curves of C. krusei, C. parapsilosis, and C. neoformans 
were linear. Among them, AMP-17 had the strong-
est antifungal effect on C. neoformans. The efficiency 
with which 100 μg/ml AMP-17 inhibited the growth of 
several common clinical pathogens was comparable to 
that of the clinical fungicide fluconazole at 100 μg/ml, 
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and the fungistatic efficiency of AMP-17 was slightly 
stronger than that of fluconazole (Fig. 1).
To better evaluate the antifungal activity of AMP-17, 
the MICs and MFCs for several common clinical 
pathogens were determined. MIC and MFC values of 
AMP-17 against C. albicans, C. tropicalis, C. krusei, and 
C. parapsilosis were 18.75 μg/ml and 37.5 μg/ml, respec-
tively. For C. neoformans, MIC and MFC values of 
AMP-17 were 9.375 μg/ml and 18.75 μg/ml, respectively 
(Table I–II). These values demonstrated that AMP-17 
exhibited significant antifungal activity against several 
common clinical pathogenic yeasts.
Physicochemical properties of AMP-17. Physical 
and chemical factors such as ionic strength, tempera-
ture, protease, and pH were some of the most impor-
tant factors that might affect the AMP activity. In the 
AMP-17 18.75 18.75 18.75 18.75 9.375
Table I
MIC values of AMP-17 against the fungi species tested.
Peptide
MIC (μg/ml)
C. albicans
ATCC10231
C. krusei
IFM56881
C. tropicalis
IFM57016
C. parapsilosis
ATCC22019
C. neoformans
IFM51426
AMP-17 37.5 37.5 37.5 37.5 18.75
Table II
MFC values of AMP-17 against the fungi species tested.
Peptide
MIC (μg/ml)
C. albicans
ATCC10231
C. krusei
IFM56881
C. tropicalis
IFM57016
C. parapsilosis
ATCC22019
C. neoformans
IFM51426
Fig. 1. Time- kill curves of the AMP-17 against the fungal species 
tested. The growth of five fungi was monitored in the presence of 
100 µg/ml AMP-17. Growth of C. albicans (A), C. tropicalis (B), 
C. krusei (C), C. parapsilosis (D), and C. neoformans with AMP-17 
were monitored by reading the optical density (OD562) of the cul-
tures. 100-μg/ml fluconazole was used as a  positive control for 
fungi. Sabouraud’s dextrose broth (0 μg/ml AMP-17) was used as 
a negative control. The OD562 values of the remaining viable cells 
were monitored in 96-well plates at different times.
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presence of NaCl and MgCl2 at a concentration from 
0 to 200 mmol, the MIC value of C. albicans increased 
with an increase in the metal ion concentration, indi-
cating a  decrease in antifungal activity for AMP-17. 
The effect of NaCl on the antifungal activity of AMP-
17 was stronger than that of MgCl2 (Fig. 2). By contrast, 
AMP-17 did not show any loss of activity when 
exposed to temperatures up to 98°C for 120 min and 
was enhanced. AMP-17 also still had a strong antifun-
gal activity after 10 cycles of freezing and thawing at 
–80°C. Therefore, the antifungal activity associated with 
AMP-17 protein was both heat tolerant and freeze-thaw 
resistant (Tables III). However, the antifungal activity 
of AMP-17 was still significant after treatment with 
trypsin, pepsin, and proteinase K for 20 min (p < 0.05). 
The antifungal activity of AMP-17 was significantly 
decreased after treatment with trypsin, pepsin and 
proteinase K for 40 min (p < 0.05). This phenomenon 
revealed that the anti-C. albicans activity of AMP-
17 decreased significantly after long treatment with 
trypsin, pepsin and protease K, indicating that AMP-17 
was sensitive to trypsin, pepsin and protease K (Fig. 3).
Hemolytic assay of AMP-17. The toxicity of the 
new AMP, AMP-17 of M. domestica, was evaluated with 
human red blood cells. The human red blood cells were 
incubated with AMP-17 at 37°C for 1 h, and the level 
  5 69.50 ± 4.95**  1 (240.50 ± 3.54**) × 102
 20 6.00 ± 2.83**  2 (273.50 ± 3.54**) × 102
 30 4.50 ± 2.12**  4 (342.00 ± 8.49**) × 102
 60 6.50 ± 0.71**  6 (357.00 ± 1.41**) × 102
 90 9.50 ± 3.54**  8 (351.50 ± 6.36**) × 102
120 3.50 ± 0.71** 10 (370.50 ± 3.54**) × 102
Negative control (ddH2O) 565900.00 ± 17112.00 Negative control (ddH2O) (5507.00 ± 147.08) × 102
Table III
Influences of temperature and the number of freeze-thaw times on the antifungal activity of AMP-17.
Note: Compared with ddH2O as a control, ** p < 0.01
Temperature (98°C)
(min)
Colony count
(x ± SD)
Temperature (–80°C)
(Times)
Colony count
(x ± SD)
0 m
mo
l/l N
aCI
0 m
mo
l/l M
gCl 2
50 
mm
ol/l 
Mg
Cl 2
50 
mm
ol/l 
NaC
I
100
 mm
ol/l 
NaC
I
100
 mm
ol/l 
Mg
Cl 2
200
 mm
ol/l 
NaC
I
200
 mm
ol/l 
Mg
Cl 2
Fig. 2. Influences of various NaCl or MgCl2 concentrations on the 
antifungal activity of AMP-17. The MIC value of AMP-17 against 
C. albicans was determined under the influence of different con-
centrations of NaCl or MgCl2 according to the conditions recom-
mended by CLSI (2008).
Fig. 3. Influences of trypsin/pepsin/proteinase K on AMP-17 when used against C. albicans. Fifty μl of the proteases
(at a concentration of 1 mg/ml) and 50 μl AMP-17 (at a concentration of 37.5 μg/ml) were mixed in a 96-well plate and placed
in a 37°C water bath for 2, 20, 40, 60, 80, 100, and 120 min. Then, it was subjected to CFU enumeration  after being treated with 100 μl
of the fungal suspension for 18 hours. PBS was used as a negative control. Compared with PBS control, *P < 0.05; **P < 0.01.
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of hemolysis was determined. Notably, the hemolysis 
rate of AMP-17 at 16 × MIC was only 1.47%, which was 
far below that of the prescribed drug standard (5%). As 
AMP-17 was not hemolytic to human red blood cells, 
it may lead to the conclusion that it has great drug 
development and application potential (Fig. 4).
Discussion
With the increase in the incidence of pathogenic 
fungal infections, antifungal drugs are increasingly 
being used in clinical practice; however, drug-resistant 
strains are also gradually increasing, posing a serious 
health problem (Loeffler and Stevens 2003). Therefore, 
the development of new natural antifungal drugs has 
become a hot topic of current research, with research 
on AMP functions from M. domestica being carried out 
in-depth. In addition to traditional AMPs, more new 
classes of high-efficiency molecules have been discov-
ered. For example, Liu et al. (2016) isolated the anti-
fungal peptide termicin from the salivary glands and 
blood cells of the termite Pseudacanthotermes spiniger. 
Iijima et al. (1993) isolated an antifungal peptide (AFP) 
from the hemolymph of Sarcophaga peregrina larvae, 
which inhibits the growth of C. albicans, causing fungal 
cytoplasmic leakage and fungal death.
Guo et al. (2017) identified AMP-17 protein as a new 
AMP, which has a strong antifungal activity against 
C. albicans. In the current study, these findings were 
advanced by evaluating antifungal spectrum, time-kill 
curves, physicochemical properties, and cytotoxicity 
of AMP-17. In vitro antifungal test results showed that 
AMP-17 protein had strong antifungal activity against 
several common clinical pathogenic fungi, with MICs 
and MFCs ranging from 9.375 μg/ml to 18.75 μg/ml and 
from 18.75 μg/ml to 37.5 μg/ml, respectively. Among 
them, AMP-17 had better antifungal activity against 
C. neoformans than other Candida species. These results 
indicated that different organisms had different bio-
logical effects, suggesting that the antifungal activity of 
AMP-17 was selective. This might be related to the sur-
face structure of the fungal cell, the type, and content of 
the membrane proteins or differences in physiological 
metabolism. Klotz et al. (1985) observed the effects of 
environmental factors on cell surface hydrophobicity 
(CSH), and found that it changed rapidly on the surface 
of C. albicans cells after changing the culture environ-
ment, while a change for C. glabrata was not obvious. 
In addition, the results of a time-sterilization dynamic 
curve showed that the fungus began to grow after 6 h 
of incubation in the PBS group, and this increased in 
an upward trend. The positive control group (FLC) 
and the experimental group (AMP-17) were almost 
inhibited by several common pathogenic yeasts within 
0–60 h, which showed the phenomenon of fungistasis 
after sterilization; however, the effect had some differ-
ences. The antifungal effect of AMP-17 on C. albicans 
Fig. 4. Hemolytic activities of AMP-17 in vitro. The diluted human red blood cells (100 μl) were incubated
with AMP-17 at 37°C for 1 h and spun at 225×g for 10 minutes. The supernatants (100 μl) were transferred
to a 96-well plate for measurement of the absorbance of the supernatants at 450 nm by the ultra-microplate
spectrophotometer. 0.1% Triton-X 100 and 0.01M PBS were used as a positive control and a negative control, respectively.
Fig. 4A is based on Fig. 4B calculated by the hemolysis rate formula. Fig. 4B was the original experimental diagram.
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and C. tropicalis was almost completely inhibited within 
0–60 h, while the antifungal effect of FLC on both was 
gradually reduced after 20 h. The antifungal effects of 
AMP-17 and FLC on C. krusei, C. parapsilosis and Cryp-
tococcus neoformans were almost completely inhibited 
within 0–60 h. Therefore, this phenomenon suggested 
that in addition to the membrane-bound fungicidal 
mode of conventional cationic AMPs, AMP-17 might 
also bind target sites in different antifungal mechanisms 
in the cytoplasm, though this needs further verification.
Although AMP-17 has good antifungal activity 
against several common clinical pathogenic fungi, its 
physicochemical properties were not known, which 
prompted us to carry out the experiments in the cur-
rent study. It was found that AMP-17 protein had good 
thermal stability, antifreeze and salt stability; however, 
its antifungal activity was easily destroyed by protease. 
Under the action of proteases (trypsin, pepsin and pro-
teinase K), the antifungal activity of AMP-17 protein 
decreased with time of treatment, to the point when 
it was lost. Tang et al. (2015) also found that an AMP 
was weakened by protease action. It was suggested 
that under certain temperature conditions, a variety of 
proteases could hydrolyze the carboxyl-terminal pep-
tide bond of AMP-17 protein, destroying the spatial 
structure of the protein and leading to loss of antifungal 
activity; however, the specific mechanisms need fur-
ther verification. In this study, it was also found that 
on exposure to a high-temperature environment (98°C) 
for 5 to 120 minutes, the antifungal activity of AMP-17 
did not decrease, but increased. This was in contrast to 
Zhang et al. (2017). The reason for the increase in activ-
ity of AMP-17 protein against C. albicans might be that 
the spatial structure of the AMP-17 protein changes 
after high-temperature treatment; however, the specific 
reasons need further verification.
Cytotoxicity, as measured by human red blood cell 
hemolysis, is an important factor in new drug devel-
opment. Hemolysis concentration-50 (HC50), as one 
of the most commonly used indicators of cytotoxicity, 
provides strong technical support in the development 
of new drugs (Konai et al. 2014). At present, although 
AMPs are expected to be the best substitute for anti-
biotics, most AMPs still show cell hemolysis, which 
limits their use as drugs. For example, Chang et al. 
(2017) found that the AMP TP4 residue A12I/A15I 
had a higher hemolytic activity, which may be due to 
the increased hydrophobicity in the main helix caused 
by the A12I/A15I mutation, which reduces bacterial 
outer membrane target protein, OprI, binding, and bac-
tericidal activity, but increases hemolytic activity. The 
phenomenon is similar to that of Chen et al. (2005), 
who also found that the hemolysis of AMP was related 
to the content of hydrophobic residues. As the hydro-
phobicity increased, the helicity and self-assembly abil-
ity of the AMP also increased. As a new type of poten-
tial AMP, the cell hemolysis characteristics of AMP-17 
could be key in drug design. Surprisingly, hemolysis by 
AMP-17 protein was much lower than the prescribed 
drug hemolysis standard (5%), making it a promising 
antifungal agent.
In conclusion, AMP-17 protein has extensive anti-
fungal activity against several common pathogens. 
Besides, it has strong stability and low hemolytic activ-
ity. These characteristics make AMP-17 protein an 
attractive molecule for development and application 
in medicine.
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